Back to Search Start Over

Research Progress of Immune Checkpoint Therapy on Colorectal Cancer

Authors :
CAO Qihua
XU Yanbo
XU Dong
Source :
Zhongliu Fangzhi Yanjiu, Vol 48, Iss 3, Pp 229-233 (2021)
Publication Year :
2021
Publisher :
Magazine House of Cancer Research on Prevention and Treatment, 2021.

Abstract

At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune checkpoint inhibitor treatment, etc, but current immunotherapy for colorectal cancer mainly focuses on immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 inhibitors). Since PD-1/PD-L1 inhibitors have shown amazing efficacy in patients with dMMR/MSI-H advanced colorectal cancer, immune checkpoint inhibitors have gained more and more attention in the field of colorectal cancer, and the treatment options have gradually shifted from late line treatment to first-line treatment or neoadjuvant therapy, and have achieved success. This paper summarizes the research progress of immune checkpoint therapy on colorectal cancer.

Details

Language :
Chinese
ISSN :
10008578
Volume :
48
Issue :
3
Database :
Directory of Open Access Journals
Journal :
Zhongliu Fangzhi Yanjiu
Publication Type :
Academic Journal
Accession number :
edsdoj.0b55c47b940c47e39f365430dae601b7
Document Type :
article
Full Text :
https://doi.org/10.3971/j.issn.1000-8578.2021.20.1060